<p>Channel Wealth LLC 在第一季度将其在安进公司（NASDAQ:AMGN - 免费报告）的持股减少了 64.8%，根据其最近向证券交易委员会（SEC）的披露。这家机构投资者在该季度出售了 3,851 股后，持有 2,090 股该医疗研究公司的股票。根据其最近的 SEC 文件，Channel Wealth LLC 在安进的持股价值为 651,000 美元。</p>
<ul>
<li>三家生物科技巨头受益于美国销售和政策变化</li>
</ul>
<p>其他一些机构投资者和对冲基金也对其在该公司的持仓进行了调整。Capital World Investors 在第四季度将其在安进的股份增加了 1,292.0%。Capital World Investors 现在拥有 6,495,710 股该医疗研究公司的股票，价值 1,693,042,000 美元，此前在上个季度又购买了 6,029,058 股。挪威银行在第四季度购买了安进的新股份，价值约为 1,541,991,000 美元。GAMMA Investing LLC 在第一季度将其在安进的股份增加了 43,573.5%。GAMMA Investing LLC 现在拥有 3,661,589 股该医疗研究公司的股票，价值 1,140,768,000 美元，此前在上个季度又购买了 3,653,205 股。Capital International Investors 在第四季度将其在安进的股份增加了 40.1%。Capital International Investors 现在拥有 12,212,065 股该医疗研究公司的股票，价值 3,182,843,000 美元，此前在上个季度又购买了 3,495,503 股。最后，查尔斯·施瓦布投资管理公司在第四季度将其在安进的股份增加了 25.4%。查尔斯·施瓦布投资管理公司现在拥有 13,205,604 股该医疗研究公司的股票，价值 3,441,909,000 美元，此前在上个季度又购买了 2,672,975 股。目前 76.50% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>安进股票表现</h2>
<p>NASDAQ:AMGN 周四开盘价为 287.01 美元。该公司的市值为 1543.3 亿美元，市盈率为 38.01，市盈增长比率为 2.63，贝塔值为 0.51。该公司的 50 日移动平均价格为 282.39 美元，200 日移动平均价格为 285.31 美元。安进的债务与股本比率为 9.62，流动比率为 1.26，速动比率为 0.95。安进公司的 12 个月最低价为 253.30 美元，12 个月最高价为 346.85 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 12/2 - 12/6</li>
</ul>
<p>安进（NASDAQ:AMGN - 获取免费报告）最近一次发布财报是在 5 月 1 日，医疗研究公司报告该季度每股收益为 4.90 美元，超出市场共识预期的 4.18 美元，超出 0.72 美元。该季度的收入为 81.5 亿美元，而分析师预期为 80.5 亿美元。安进的股本回报率为 176.32%，净利润率为 12.24%。安进该季度的收入较去年同期增长了 9.4%。在去年同期，该公司每股收益为 3.96 美元。平均而言，卖方分析师预计安进公司在当前财年将发布每股收益 20.62 美元。</p>
<h2>分析师评级变动</h2>
<p>几位研究分析师最近对该公司进行了评估。Guggenheim 在 5 月 20 日的报告中开始覆盖安进，给予 “中性” 评级和 288.00 美元的目标价。富国银行在 2 月 5 日的报告中重申了对安进股票的 “持平” 评级。Erste Group Bank 在 5 月 8 日的报告中将安进的评级从 “强力买入” 下调至 “持有”。花旗集团在 2 月 5 日的报告中重申了对安进股票的 “中性” 评级。最后，美国银行在 3 月 5 日的报告中将安进的目标价从 275.00 美元上调至 294.00 美元，并给予该公司 “表现不佳” 的评级。两位股票研究分析师给予该股票 “卖出” 评级，十二位给予 “持有” 评级，九位给予 “买入” 评级，二位给予 “强力买入” 评级。根据 MarketBeat 的数据，安进目前的平均评级为 “持有”，共识目标价为 309.22 美元。</p>
<ul>
<li>安进股票因减肥药数据下跌：过度反应还是合理？</li>
</ul>
<p><strong>查看我们对安进的最新分析</strong></p>
<h2>安进简介</h2>
<p>（免费报告）</p>
<p>安进公司在全球范围内发现、开发、生产和交付人类治疗药物。该公司的主要产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病关节炎的恩利昔单抗；用于治疗成人斑块型银屑病、银屑病关节炎和与贝赫切特病相关的口腔溃疡的 Otezla；用于治疗绝经后女性骨质疏松症的 Prolia；用于预防骨骼相关事件的 XGEVA；可减少心肌梗死、中风和冠状血管重建风险的 Repatha；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的 Aranesp；用于治疗绝经后男性和女性骨质疏松症的 EVENITY；用于治疗野生型 RAS 转移性结直肠癌患者的 Vectibix；用于治疗急性淋巴细胞白血病患者的 BLINCYTO；用于治疗甲状腺眼病的 TEPEZZA；以及用于治疗慢性难治性痛风的 KRYSTEXXA。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票超过安进</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>Intuit 的人工智能热潮：股票飙升，但投资者应该暂停吗？</li>
<li>选举股票：选举如何影响股市</li>
<li>强分析师评级的顶级分红股票</li>
<li>ETF 支付分红吗？你需要知道的</li>
<li>Robinhood 股票持续给投资者买入理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在安进吗？</h2>
<p>在考虑安进之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而安进并不在名单上。</p>
<p>虽然安进目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

安进

<p>Channel Wealth LLC 在第一季度减少了对安进（Amgen Inc.，NASDAQ:AMGN）64.8% 的持股，目前持有 2,090 股，价值 65.1 万美元。其他机构投资者，包括 Capital World Investors 和 GAMMA Investing LLC，显著增加了对安进的持仓。该股票开盘价为 287.01 美元，市值为 1543.3 亿美元。安进报告第一季度每股收益为 4.90 美元，超出预期，营收为 81.5 亿美元，同比增长 9.4%。分析师对该股票的评级不一，平均评级为 “持有”，共识目标价为 309.22 美元</p>

<p>Channel Wealth LLC cut its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 64.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,090 shares of the medical research company's stock after selling 3,851 shares during the quarter. Channel Wealth LLC's holdings in Amgen were worth $651,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Channel Wealth LLC 在第一季度将其在安进公司（NASDAQ:AMGN - 免费报告）的持股减少了 64.8%，根据其最近向证券交易委员会（SEC）的披露。这家机构投资者在该季度出售了 3,851 股后，持有 2,090 股该医疗研究公司的股票。根据其最近的 SEC 文件，Channel Wealth LLC 在安进的持股价值为 651,000 美元。</p>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>三家生物科技巨头受益于美国销售和政策变化</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also made changes to their positions in the business. Capital World Investors increased its stake in Amgen by 1,292.0% during the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock worth $1,693,042,000 after buying an additional 6,029,058 shares in the last quarter. Norges Bank purchased a new stake in Amgen during the 4th quarter worth approximately $1,541,991,000. GAMMA Investing LLC increased its stake in Amgen by 43,573.5% during the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock worth $1,140,768,000 after buying an additional 3,653,205 shares in the last quarter. Capital International Investors increased its stake in Amgen by 40.1% during the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after buying an additional 3,495,503 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after purchasing an additional 2,672,975 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金也对其在该公司的持仓进行了调整。Capital World Investors 在第四季度将其在安进的股份增加了 1,292.0%。Capital World Investors 现在拥有 6,495,710 股该医疗研究公司的股票，价值 1,693,042,000 美元，此前在上个季度又购买了 6,029,058 股。挪威银行在第四季度购买了安进的新股份，价值约为 1,541,991,000 美元。GAMMA Investing LLC 在第一季度将其在安进的股份增加了 43,573.5%。GAMMA Investing LLC 现在拥有 3,661,589 股该医疗研究公司的股票，价值 1,140,768,000 美元，此前在上个季度又购买了 3,653,205 股。Capital International Investors 在第四季度将其在安进的股份增加了 40.1%。Capital International Investors 现在拥有 12,212,065 股该医疗研究公司的股票，价值 3,182,843,000 美元，此前在上个季度又购买了 3,495,503 股。最后，查尔斯·施瓦布投资管理公司在第四季度将其在安进的股份增加了 25.4%。查尔斯·施瓦布投资管理公司现在拥有 13,205,604 股该医疗研究公司的股票，价值 3,441,909,000 美元，此前在上个季度又购买了 2,672,975 股。目前 76.50% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Amgen Stock Performance</h2>
<div class="lb-trans"><h2>安进股票表现</h2>
</div><p>NASDAQ:AMGN opened at $287.01 on Thursday. The firm has a market capitalization of $154.33 billion, a PE ratio of 38.01, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The business's fifty day moving average price is $282.39 and its 200 day moving average price is $285.31. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.</p>
<div class="lb-trans"><p>NASDAQ:AMGN 周四开盘价为 287.01 美元。该公司的市值为 1543.3 亿美元，市盈率为 38.01，市盈增长比率为 2.63，贝塔值为 0.51。该公司的 50 日移动平均价格为 282.39 美元，200 日移动平均价格为 285.31 美元。安进的债务与股本比率为 9.62，流动比率为 1.26，速动比率为 0.95。安进公司的 12 个月最低价为 253.30 美元，12 个月最高价为 346.85 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 12/2 - 12/6</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 12/2 - 12/6</li>
</ul>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Amgen's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.96 earnings per share. On average, sell-side analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）最近一次发布财报是在 5 月 1 日，医疗研究公司报告该季度每股收益为 4.90 美元，超出市场共识预期的 4.18 美元，超出 0.72 美元。该季度的收入为 81.5 亿美元，而分析师预期为 80.5 亿美元。安进的股本回报率为 176.32%，净利润率为 12.24%。安进该季度的收入较去年同期增长了 9.4%。在去年同期，该公司每股收益为 3.96 美元。平均而言，卖方分析师预计安进公司在当前财年将发布每股收益 20.62 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research analysts have recently weighed in on the company. Guggenheim assumed coverage on Amgen in a report on Tuesday, May 20th. They set a &#34;neutral&#34; rating and a $288.00 target price on the stock. Wells Fargo &amp; Company restated an &#34;equal weight&#34; rating on shares of Amgen in a report on Wednesday, February 5th. Erste Group Bank cut Amgen from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, May 8th. Citigroup restated a &#34;neutral&#34; rating on shares of Amgen in a report on Wednesday, February 5th. Finally, Bank of America upped their price objective on Amgen from $275.00 to $294.00 and gave the company an &#34;underperform&#34; rating in a report on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of &#34;Hold&#34; and a consensus price target of $309.22.</p>
<div class="lb-trans"><p>几位研究分析师最近对该公司进行了评估。Guggenheim 在 5 月 20 日的报告中开始覆盖安进，给予 “中性” 评级和 288.00 美元的目标价。富国银行在 2 月 5 日的报告中重申了对安进股票的 “持平” 评级。Erste Group Bank 在 5 月 8 日的报告中将安进的评级从 “强力买入” 下调至 “持有”。花旗集团在 2 月 5 日的报告中重申了对安进股票的 “中性” 评级。最后，美国银行在 3 月 5 日的报告中将安进的目标价从 275.00 美元上调至 294.00 美元，并给予该公司 “表现不佳” 的评级。两位股票研究分析师给予该股票 “卖出” 评级，十二位给予 “持有” 评级，九位给予 “买入” 评级，二位给予 “强力买入” 评级。根据 MarketBeat 的数据，安进目前的平均评级为 “持有”，共识目标价为 309.22 美元。</p>
</div><ul>
<li>Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?</li>
</ul>
<div class="lb-trans"><ul>
<li>安进股票因减肥药数据下跌：过度反应还是合理？</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on Amgen</strong></p>
<div class="lb-trans"><p><strong>查看我们对安进的最新分析</strong></p>
</div><h2>Amgen Profile</h2>
<div class="lb-trans"><h2>安进简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p>
<div class="lb-trans"><p>安进公司在全球范围内发现、开发、生产和交付人类治疗药物。该公司的主要产品包括用于治疗斑块型银屑病、类风湿性关节炎和银屑病关节炎的恩利昔单抗；用于治疗成人斑块型银屑病、银屑病关节炎和与贝赫切特病相关的口腔溃疡的 Otezla；用于治疗绝经后女性骨质疏松症的 Prolia；用于预防骨骼相关事件的 XGEVA；可减少心肌梗死、中风和冠状血管重建风险的 Repatha；用于治疗免疫性血小板减少症患者的 Nplate；用于治疗复发性或难治性多发性骨髓瘤患者的 KYPROLIS；用于治疗红细胞数量低于正常水平和贫血的 Aranesp；用于治疗绝经后男性和女性骨质疏松症的 EVENITY；用于治疗野生型 RAS 转移性结直肠癌患者的 Vectibix；用于治疗急性淋巴细胞白血病患者的 BLINCYTO；用于治疗甲状腺眼病的 TEPEZZA；以及用于治疗慢性难治性痛风的 KRYSTEXXA。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>Canadian Penny Stocks: Can They Make You Rich?</li>
<li>Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause?</li>
<li>Election Stocks: How Elections Affect the Stock Market</li>
<li>Top Dividend Plays With Strong Analyst Ratings</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Robinhood Stock Keeps Giving Investors Reasons To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过安进</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>Intuit 的人工智能热潮：股票飙升，但投资者应该暂停吗？</li>
<li>选举股票：选举如何影响股市</li>
<li>强分析师评级的顶级分红股票</li>
<li>ETF 支付分红吗？你需要知道的</li>
<li>Robinhood 股票持续给投资者买入理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在安进吗？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑安进之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而安进并不在名单上。</p>
</div><p>While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然安进目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Channel Wealth LLC 削减了其在安进公司（NASDAQ:AMGN）的股票头寸